Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Google to Move All Pixel Production Out of China by 2027 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Add as a preferred source on Google
Top South Korean cosmetics maker Amorepacific Corp. suffered a net loss of 58.9 billion won in the fourth quarter, increasing 1.7 percent from the 57.9 billion won a year ago, mainly due to the pandemic's impact.
According to the firm, it endured a decrease in offline and duty-free sales with the spread of COVID-19 limiting local shopping and reducing the number of inbound tourists.
However, online sales soared by about 50 percent.
The company also posted a 9.2 million won operating loss in the quarter, after enjoying a 45.9 billion won operating profit during the same period a year before. Sales plunged 13.3 percent to 1.16 trillion won during the said period.
For 2020, Amorepacific Corp. recorded a net profit of 21.9 billion won, down 90.2 percent from 2019. Operating income plunged 66.6 percent on-year to 143 billion won, as sales dropped 20.6 percent to 4.43 trillion won.
The Amorepacific Group, which includes Innisfree and Etude, logged a net income of 22 billion, down 92.2 percent from the previous year. The group's operating profit also slumped 69.8 percent on-year to 150.7 billion won, and sales plummeted 21.5 percent to 4.93 trillion won.
